NK3R Inhibitor Crystal Forms for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for menopausal hot flashes, such as hormone replacement therapy and oral drugs, pose significant health risks and have limited efficacy, necessitating the development of safer and more effective NK3R inhibitor compounds with improved solubility, solid stability, and bioavailability.
Innovation Solution
The development of specific crystal forms and acidic salts of the NK3R inhibitor compound, including hydrochloride, methanesulfonate, nitrate, and sulfate forms, with defined X-ray powder diffraction patterns, to enhance solubility, stability, and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hormone replacement therapy is used to treat menopausal hot flashes, then the therapeutic effectiveness is improved, but the health risks and safety concerns increase
Solution Approach 1:
The patent applies parameter changes by developing multiple salt forms (hydrochloride, methanesulfonate, nitrate, sulfate) and crystal forms of the NK3R inhibitor compound. These different physical and chemical forms allow optimization of pharmacokinetic parameters such as solubility, stability, and bioavailability, enabling effective treatment without the harmful effects of hormone replacement therapy
Solution Approach 2:
The patent develops small molecule NK3R inhibitor compounds that can be administered orally and have short half-lives, allowing for controlled, temporary inhibition of NK3R receptors. This approach provides therapeutic benefit without the long-term cumulative risks associated with hormone replacement therapy
2Ease of manufacture
If conventional oral drugs are used for menopausal hot flashes, then the treatment is approved and available, but the side effects and safety profile worsen
Solution Approach 1:
The patent segments the treatment approach by developing distinct salt and crystal forms of the NK3R inhibitor, each with optimized properties for different aspects of drug performance. This segmentation allows the compound to meet multiple requirements (solubility, stability, bioavailability) that conventional single-form drugs cannot satisfy, providing a safer alternative with improved side effect profile
3Ease of manufacture
If the NK3R inhibitor compound is developed in standard form, then the synthesis is straightforward, but the solubility and bioavailability are insufficient
Solution Approach 1:
The patent changes the physical and chemical parameters of the NK3R inhibitor compound by converting it into different salt forms (hydrochloride, methanesulfonate, nitrate, sulfate) and crystal forms. These parameter changes dramatically improve solubility and bioavailability while maintaining the core molecular structure and biological activity, thus preserving ease of manufacture through well-established salt formation methodologies
4Ease of manufacture
If the product is stored in standard conditions, then the storage costs are low, but the solid stability deteriorates
Solution Approach 1:
The patent utilizes phase transitions by developing specific crystal forms of the NK3R inhibitor compound. The crystalline phase provides enhanced solid stability compared to amorphous or hydrated forms, allowing the product to maintain composition integrity under standard storage conditions. The different crystal forms exhibit varying stability profiles, enabling selection of the optimal form for long-term storage
Data Source
AI summary
The present invention relates to an acidic salt or a crystal form of a nitrogen-containing fused ring derivative inhibitor, and a preparation method therefor and the use thereof. The salt or crystal form of the inhibitor of the present invention can be used for treating related diseases such as depression, anxiety disorder, schizophrenia and sex hormone dependence, and has broad application prospects.